ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← All editions

THE ARISING · EDITED READER EDITION

The Arising · November 19 Edited Reader Edition

This edited reader edition includes 11 reviewed articles from November 19, 2026. It is not the complete original issue. It includes 11 of the original 47 stories; 36 are not included here.

Longevity & Healthspan

At-home gut tests gave different answers from the same stool

Seven services analyzed the same reference sample. The findings challenge repeatability, not the value of studying the microbiome.

The same reference material sent to seven commercial gut-testing services produced reports that differed, sometimes even across kits from the same provider.

That is the central result of a laboratory study in Communications Biology, led by Stephanie Servetas and colleagues at the US National Institute of Standards and Technology (NIST). It is an analytical test of the products, not a study of health outcomes in people. The team ordered three kits from each of seven direct-to-consumer services, 21 kits in all, and loaded every kit with a homogenized pool of human fecal material that NIST developed as a reference standard. Because the material was uniform, any differences in the reports came from the testing, not the sample.

The companies were not told about the assessment until all the final reports had come back, between 2 and 8 weeks after shipping. The authors report major discrepancies both across providers and within them. Their key finding: for many of the shared groups of microbes they examined, differences among methods were comparable to differences between donors. To make that comparison, NIST also analysed material from seven other donors with its own method. In effect, the choice of company changed the picture about as much as swapping one person's gut for another's.

The reports differed in basic ways. Some companies sequenced a single marker gene, the 16S rRNA gene. Others read all the DNA in the sample, a method called whole metagenome shotgun sequencing. One also looked for fungi. The number of sequence reads ranged from under 20,000 to more than 10 million. More reads did not mean more species found. Company C reported over 600 species from between 20,000 and 30,000 reads. Company D reported 95, 98 and 99 species across its three kits, each with more than 10 million reads.

The cutoffs for reporting a microbe also varied widely, from 0.1% of the sample down to 8 × 10⁻⁶ %. Collection instructions differed too: whole bowel movement or used toilet paper, different sampling tools, and a buffer liquid in some kits but not others. No kit included ice, so every sample travelled at ambient temperature. The authors attribute the differences to methodological variability and a lack of sufficient quality control. They add that reliable measurement is a prerequisite for sound clinical recommendations, and they call for standards.

The study tested the consistency of reports for one standardized specimen. It did not test whether following a company’s diet or supplement advice improves health. Improving measurement would be a prerequisite for answering that separate question.

Sources

Open this article on its own → Explore the Microbiome Living Magazine →

Longevity & Healthspan

Strength training modestly eased depressive symptoms in randomized trials

The average edge was smaller when compared with another active program.

In a JAMA Network Open analysis, resistance training reduced depression symptom scores on average. The difference was smaller against other active options than against no added treatment or similar inactive comparison groups.

The work is a meta-analysis, a study that pools results from many earlier trials. It was published in JAMA Network Open in 2026 by O'Sullivan, Herring and colleagues. The team combined 80 randomized clinical trials with 6,123 participants. Of these, 2,880 were assigned to resistance exercise training and 3,243 to comparison conditions. The average age was 57.

The researchers searched five databases, including MEDLINE, PubMed and PsycInfo, for studies published up to July 7, 2025. Each trial had to include at least 3 weeks of resistance exercise training, or a comparison condition, and a validated measure of depressive symptoms. Across the 80 trials, they examined 176 effect sizes. Fifty-seven of the trials enrolled people with an illness.

Comparison groups fell into two types. Inactive comparisons were no treatment, waiting lists and continued usual care. Active comparisons included aerobic exercise, relaxation, flexibility work, mind-body exercise, nutrition, education, advice or attention, mixed activities and balance exercises.

Overall, resistance exercise training was associated with a significant reduction in depressive symptoms. The pooled effect size was 0.32 (95% confidence interval 0.25 to 0.39). The authors describe this result as small in magnitude. Results varied considerably between trials.

The difference was clearer against inactive comparisons: 0.54 standard deviations (95% confidence interval 0.39 to 0.68), versus 0.21 (0.14 to 0.27) against active comparisons. The latter group covered a range of activities, so this is not a head-to-head finding against each alternative. The outcome was change in symptom scores, not proof that lifting replaces medication or psychotherapy.

In trials with an inactive comparison, the estimated benefit was smaller when treatment allocation was concealed. Only 12 trials reported follow-up after the intervention, leaving the persistence of any benefit less certain. That makes resistance training worth studying as part of care, without assuming it is a substitute for other care.

Sources

Open this article on its own → Explore the Fitness Living Magazine →

Longevity & Healthspan

Could an ordinary chest X-ray help flag fracture risk?

In people already referred for bone-density testing, an AI model ranked fracture risk better than FRAX with bone density. It has not been shown to prevent fractures.

The same image taken to check the chest might eventually offer a second clue, about the likelihood of a major bone fracture. The evidence so far is from people who also had a bone-density scan.

The evidence comes from a cohort study published in NEJM AI in 2026. Researchers led by Kim and Kong built a computer model using 53,109 adults at one tertiary hospital. They then tested it in 85,284 patients at two separate institutions. The outcome was a major osteoporotic fracture: a break of the kind most tied to weak bones.

Doctors usually judge fracture risk with bone mineral density, measured by a dual-energy X-ray absorptiometry scan, and with FRAX, the Fracture Risk Assessment Tool. According to the paper, both capture risk incompletely in the osteopenic range. Osteopenia is the borderline zone between healthy bone and osteoporosis, and the authors note that much of the fracture burden occurs there.

The new model is a convolutional neural network, a type of image-analysis AI, built to estimate risk over time. It looks at an ordinary chest radiograph. That makes it an opportunistic approach: it uses an image already taken, with no added scan or radiation visit.

In the external validation groups, participants averaged 58.6 years of age, 68.9% were female, and follow-up averaged 77 months. The model reached a C-index of 0.843 (95% confidence interval, 0.837 to 0.850). The C-index measures how well a tool ranks people, so that those who go on to fracture are scored as higher risk than those who do not. A score of 0.5 is chance and 1.0 is perfect.

FRAX with bone density scored 0.779 (95% confidence interval, 0.770 to 0.787). For the 10-year area under the receiver operating characteristic curve, another measure of how well a test separates people who fracture from those who do not, the model scored 0.855 against 0.785 for FRAX with bone density.

In the 35,358-person osteopenia subgroup, the model’s 10-year discrimination score was 0.779, versus 0.659 for FRAX with bone density. That is the group where a bone density result alone often leaves the next step unclear. They conclude that the model identified patients at high fracture risk with discrimination exceeding that of FRAX.

Every participant had already been referred for a bone density scan. The authors say that estimates of absolute risk and of how many cases the approach would find need prospective testing in an unselected group of people having routine chest radiographs.

That testing is the next thing to watch. The next step would be to see how many people are accurately flagged in ordinary X-ray practice, how often unnecessary follow-up happens, and whether acting on an alert prevents fractures. This study measured risk ranking, not those real-world consequences.

Sources

Open this article on its own → Explore the Bone Health Living Magazine → Explore the Clinical AI Living Magazine →

Longevity & Healthspan

An experimental blood marker distinguished a precursor to ovarian cancer

A study using known tissue diagnoses found a strong signal. That is not a validated screening test.

A blood marker separated people with a known fallopian tube precursor lesion from those with normal tissue or benign growths in a research comparison.

The work, published in Nature Medicine by Wilhelm and colleagues, is a peer-reviewed study in people. The researchers measured an RNA molecule called Tu-stroma in blood serum from 506 individuals. The groups were 143 with histologically normal adnexa (the ovaries and fallopian tubes), 88 with benign growths in that area, 43 with the precursor lesion on its own, and 232 with high-grade serous carcinoma.

High-grade serous carcinoma is the most common type of epithelial ovarian cancer and the leading cause of ovarian-cancer deaths, according to the paper. It arises from a lesion called serous tubal intraepithelial carcinoma, or STIC. STIC has not spread into surrounding tissue. It is typically identified only when a pathologist examines fallopian tube tissue after it has been removed.

Tu-stroma is a long noncoding RNA, a type of RNA that does not make a protein. It travels in extracellular vesicles, tiny packets that cells release into the blood. Here the question was whether measuring this RNA distinguished people whose tissue already had a known diagnosis.

Levels of Tu-stroma in vesicles were higher in women with STIC and in those with high-grade serous carcinoma than in controls and in women with benign growths. This held in premenopausal women too, a group of 211 within the larger cohort.

The researchers compared the RNA with CA125, the protein marker most often used in ovarian cancer testing. They used a measure called area under the curve, where 1.0 is a perfect test and 0.5 is no better than chance. For STIC versus controls, Tu-stroma scored 0.99 and CA125 scored 0.59. For STIC versus benign growths, the scores were 0.99 and 0.31.

For high-grade serous cancer, the gap was narrower. Tu-stroma scored 0.99 against controls, compared with 0.96 for CA125. Against benign growths, it scored 0.98 against 0.84.

The RNA also showed no systematic rise in 116 samples from people with inflammatory or physiologic conditions, or in 160 samples from people with cancers outside the ovary. Each group was compared with 100 healthy controls. The authors say this supports specificity to the ovarian disease setting.

The authors also modeled higher-risk groups to estimate predictive values, rather than measuring those values through a real screening program. They call Tu-stroma a candidate marker linked to pre-invasive and early disease. They note that prospective testing in consecutively enrolled, real-world cohorts is required to confirm how well it performs and whether it is clinically useful.

An excellent score for telling apart known groups does not tell us how many positive tests would be false alarms in a population where the lesion is rare. A prospective study must also show whether an alert leads to care that does more good than harm.

Sources

Open this article on its own → Explore the Cancer Screening Living Magazine →

Longevity & Healthspan

An experimental blood assay tracked advanced tau tangles

Four research cohorts show a promising proxy for advanced pathology, not yet a clinical test.

A new blood assay measured a tau fragment that was more abundant among people with widespread tangles. The researchers call it a proof of principle.

The work, published in JAMA in 2026, is a cross-sectional study of 728 participants in four cohorts. Two were US autopsy cohorts of brain donors who had given blood before death (240 and 241 people). Two were imaging cohorts in Canada and Sweden, where people had plasma samples and tau PET scans. Visits took place between 2002 and 2025, depending on the cohort.

Tau is a protein that forms tangles inside brain cells in Alzheimer's disease. Pathologists grade tangle spread in Braak stages. Stage I means tangles are confined to the entorhinal region, a small area deep in the brain. Stage VI means tangles have spread widely across the neocortex, the brain's outer layer.

The researchers measured a fragment called eMTBR-tau, from the microtubule-binding region of tau, using a new immunoassay. This is a lab format that can be scaled up more easily than mass spectrometry, which earlier work had used to measure the related fragment eMTBR-tau243.

In comparisons across participants in the autopsy cohorts, plasma levels were higher at more advanced Braak stages. In the first cohort, the age- and sex-adjusted geometric mean was 0.0021 pg/mL at stages I-II and 0.107 pg/mL at stage VI, a 50.5-fold difference (95% CI, 26.3-97.0). In the second, it was 0.0040 pg/mL versus 0.101 pg/mL, a 25.2-fold difference (95% CI, 15.8-40.3).

The test was also compared with brain scans. Tau PET shows tangles in living people, and higher uptake values mean more tangles. The study examined how plasma levels related to regional tau-PET uptake and to tau-PET positivity. The immunoassay also correlated strongly with mass spectrometry measurements of eMTBR-tau243.

The authors conclude that the immunoassay identified neocortical tau pathology in both the autopsy and the PET cohorts. They describe the result as a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced tangle pathology.

The authors note that blood biomarkers reflecting tangle burden remain limited. A blood measure of advanced tangles could add to existing tests, and brain imaging is costlier and less widely available.

This study did not follow individual blood levels as disease progressed or show that the assay could guide treatment. Independent validation and prospective clinical testing would be needed before answering either question.

Sources

Open this article on its own → Explore the Brain Living Magazine →

Longevity & Healthspan

In suspected heart attack, troponin beat an AI reading of the ECG

Putting the two together improved statistical performance slightly. Better emergency care still needs to be demonstrated.

In two European groups of emergency patients with a suspected heart attack, the standard high-sensitivity troponin T blood test distinguished cases better than this AI reading of the first heart tracing.

That is the finding of a prospective diagnostic cohort study in The Lancet Regional Health – Europe. It followed 12,630 emergency patients with suspected heart attack, drawn from two European cohorts, APACE (5,047 patients) and APACE-Light (7,583 patients). Heart attacks were confirmed by central adjudication under the fourth Universal Definition of Myocardial Infarction. They were diagnosed in 19% of APACE patients (968) and 18% of APACE-Light patients (1,386).

The tool, called AiTiA MI, was built using data from Korean patients. The researchers applied it to the 12-lead ECG recorded when each patient arrived. They compared it with high-sensitivity cardiac troponin T, the BASEL score, the recalibrated HEART score and physician judgment at 90 minutes. The last two were available only in APACE.

Accuracy was measured by the area under the curve, or AUC. A score of 1.0 means perfect separation of patients with and without a heart attack. The AI-ECG scored 0.78 in APACE and 0.84 in APACE-Light. The troponin T test scored 0.94 and 0.93.

Combining the two helped a little. The AI-ECG added some diagnostic value to troponin T, lifting the AUC to 0.95 in both cohorts. The authors describe the AI-ECG's accuracy as high, but not very high.

The authors conclude that a heart attack is unlikely to be ruled out on an ECG alone. Their view is that pairing AI-ECG with the blood test may improve decision making in the emergency department. They say this warrants prospective studies.

The work was funded by the Swiss National Science Foundation, the Swiss Heart Foundation, Innosuisse, the University Hospital Basel, the University of Basel and the Korea Health Industry Development Institute. Several diagnostics companies, including Abbott, Roche, Siemens and Beckman Coulter, also provided funding.

A higher AUC is not evidence that an AI alert leads to faster correct treatment or fewer missed heart attacks. The team calls for studies that test the combination within emergency care. This particular ECG model did not outperform troponin and the results do not support using it in place of standard evaluation.

Sources

Open this article on its own → Explore the Clinical AI Living Magazine → Explore the Cardiovascular Living Magazine →

Longevity & Healthspan

A hospital mobility program did not clearly help older patients move more

The Swiss trial tested education and ward changes, not extra supervised rehabilitation.

A Swiss ward-level trial found no clear gain in how far or how often older patients moved in everyday life 30 days after enrollment.

The study was a cluster randomised clinical trial. Whole hospital wards, not individual patients, were assigned by chance to the program or to standard care. It ran on acute general internal medicine wards at 3 Swiss hospitals. Of 1334 eligible patients, 383 agreed to take part. They were spread across 12 wards, with 183 in the intervention group and 200 in the control group.

Participants were aged 60 or older and lived in the community before admission. Their median age was 75, and 234 (61.1%) were men. The median hospital stay was 5 days.

Low movement during a hospital stay is common, the authors write, and it is linked to loss of independence and death. Earlier programs that got patients moving more needed staff and resources that most wards do not have. The research team, led by Schiffmann, tested a program built to be practical in everyday care. It is called INTOMOB, short for Intervention to Increase Mobility in Older Hospitalized Medical Patients.

INTOMOB had three parts: booklets and videos for patients, training for health care professionals, and posters in the wards.

The main measure was life-space mobility at 30 days. This score captures how far and how often a person moves through their surroundings, from the bedroom to beyond their town. It runs from 0 to 120, and higher scores mean more mobility. Data were available for 327 patients (85.4%).

The trial found no statistically clear difference between groups. The adjusted difference was 0.67 points, with a 95% confidence interval from −4.35 to 5.68. That range includes no difference at all.

The program also showed no consistent, statistically significant effect on the secondary outcomes. These were physical activity during the hospital stay, new moves into a nursing home, and quality of life. The researchers reported no serious adverse events potentially related to the intervention.

For families, the result bears on what a hospital's mobility effort actually involves. In this trial, information for patients, staff training and ward posters did not translate into greater movement at 30 days. The authors note that the programs that did raise hospital mobility in earlier work relied on resources not available in routine practice.

There was no clear difference in life-space mobility at 180 days either. One limit is that usual care in the participating hospitals already emphasized mobility. The result applies to this education-based package; it does not show that dedicated, supervised rehabilitation has no benefit.

Sources

Open this article on its own → Explore the Fitness Living Magazine →

Longevity & Healthspan

AI helped less-experienced colonoscopists detect more adenomas

Five randomized trials showed no clear gain in finding advanced adenomas, and did not establish fewer cases of cancer.

In five randomized trials, trainees and less-experienced doctors using computer assistance found adenomas more often than those using standard colonoscopy. No clear increase was shown for advanced adenomas.

The study is a systematic review and meta-analysis, published in 2026 in Gastroenterology Research. The authors combined five randomized controlled trials covering 3,158 patients. Each trial compared colonoscopy with computer-aided detection (CADe) against standard colonoscopy, performed by trainees or less-experienced endoscopists. CADe software flags suspicious areas on the screen as the doctor examines the colon.

The main measure was the adenoma detection rate. An adenoma is a type of polyp that can turn into colon cancer, so finding and removing them is a central goal of the exam. With CADe, the rate was higher by a risk ratio of 1.17 (95% confidence interval 1.07 to 1.29). That works out to an absolute gain of 6.9 percentage points. That works out to about 15 examinations for one additional patient with an adenoma detected, on average. It does not mean one cancer prevented.

The gain was larger in the right side of the colon. There, the risk ratio was 1.31 (95% confidence interval 1.14 to 1.50), an absolute gain of 8.2 percentage points. The overall polyp detection rate was also higher, with a risk ratio of 1.16.

Advanced adenomas are the larger or more worrying polyps. Here the picture was different. The detection rate did not differ between the CADe and standard groups (risk ratio 0.97, 95% confidence interval 0.73 to 1.29).

The overall result held up when the authors removed each trial in turn. It also held when they dropped the one trial of independently practicing, non-expert operators and looked only at doctors in formal training (risk ratio 1.16, 95% confidence interval 1.01 to 1.33).

The authors rated their confidence in the evidence as moderate for overall adenoma detection. It was low for right-colon and overall polyp detection, and very low for advanced adenomas. Their prediction intervals, which estimate the range of effects in future settings, crossed the point of no effect for the main results.

The additional findings in these trials were not shown to translate to fewer cancers or improved outcomes. The trials also say little about what happens when operators later perform the procedure without the software.

The authors conclude that the findings support further prospective evaluation of CADe as an adjunct to colonoscopy training. They say the results do not establish that building it into fellowship curricula produces more competent independent endoscopists.

What to watch next: larger trials in trainees and less-experienced operators, with a focus on whether CADe raises detection of advanced adenomas and right-colon polyps.

Sources

Open this article on its own → Explore the Cancer Screening Living Magazine → Explore the Clinical AI Living Magazine →

Longevity & Healthspan

Home exercise may improve strength and function in older adults with sarcopenia

A review of 12 randomized trials found more consistent changes in function than in muscle mass.

The review found a pattern of better strength and movement after home exercise, but the studies varied too much to combine into a single estimate.

Sarcopenia is the age-related loss of muscle mass, strength and function. It can severely reduce independence in older adults. Exercise is the main way it is managed, and the review's authors note that home-based programs are accessible, cost-effective and sustainable for long-term rehabilitation.

The review synthesized evidence from randomized controlled trials, the kind of study in which people are assigned by chance to an intervention or a comparison group. The authors searched four databases for English-language trials published between January 2016 and 28 February 2026. They included 12 trials with 928 participants: 513 in the intervention groups and 415 in the control groups. All participants were older adults diagnosed with sarcopenia. The authors rated the methodological quality of the trials as moderate to good.

Most of the programs were multicomponent, meaning they combined several types of exercise, and predominantly included resistance training. They typically lasted about 12 weeks. Across the trials, home-based exercise was generally associated with improvements in muscle strength, physical performance including balance, and quality of life.

Results for muscle mass and body composition were inconsistent. Some trials showed changes and others did not, so the review does not point to a clear effect on how much muscle people carried.

The trials used different diagnostic criteria, exercise protocols, outcome measures and follow-up periods, which prevented the authors from combining the results into a single statistical estimate.

The authors conclude that home-based exercise, particularly resistance-focused and multicomponent programs, may improve physical and functional outcomes in older adults with sarcopenia.

Participants usually knew which intervention they were doing, and the authors rated that as a high risk of performance bias across studies. This review does not establish an optimal exercise prescription or whether any specific program changes long-term independence.

Sources

Open this article on its own → Explore the Muscle Living Magazine →

Longevity & Healthspan

Earlier menopause was linked to more chronic illness later in life

Three long-running cohorts found an association at age 45 or younger. The study did not test whether an intervention could change it.

When menopause happens may tell clinicians something about which patients are more likely to accumulate chronic conditions. In three cohorts from the United States, England and Mexico, women who reported reaching menopause at 45 or younger were more likely to develop multiple chronic conditions during later-life follow-up than those who reported menopause at 50 or 51.

Tao-Ming Dai and colleagues analyzed 6,576 women who began follow-up with no more than one of seven conditions: high blood pressure, diabetes, cancer, chronic lung disease, heart disease, stroke, and arthritis or rheumatism. A new case was counted at the first follow-up interview at which at least two of those conditions were reported. Over an average of 5.55 years, the researchers observed 2,031 new cases.

Compared with menopause at 50 or 51, the adjusted hazard ratio was 1.22 for menopause at 40 or younger (95% confidence interval, 1.05 to 1.41), and 1.21 for ages 41 to 45 (1.05 to 1.40). That is a relative comparison of how quickly new cases appeared, not a 21-point increase in an individual's chance of developing disease. There was no clear increase in the other age groups compared with the reference group.

Menopause age and diagnoses were largely self-reported. Follow-up began at the study baseline, not at menopause, and the available data could not consistently distinguish reasons for menopause or account for menopausal hormone therapy. The study cannot show that earlier menopause caused the difference, or whether hormone therapy or a different screening schedule would change it.

The next question is whether adding menopause timing to what clinicians already know improves decisions and, ultimately, outcomes. This study identifies a possible marker. It does not establish that acting on it prevents disease.

Primary source

Open this article on its own → Menopause & Hormone Therapy Living Magazine →

Longevity & Healthspan

Lab studies suggest how calcium deposits may spread across an aortic valve

Research in donated human tissue, cultured cells and mice points to Gas6. It does not identify a treatment that has worked in patients.

Calcium deposits can start in small patches on an aortic valve. As the valve stiffens, it can become harder for blood to pass from the heart into the aorta. The question in an Aging Cell study was how a patch of calcification might affect the tissue next to it.

The team studied valves from 24 surgical patients, including 12 with severe calcific valve disease and 12 with a leaking valve but no calcification. That comparison group had valve disease of its own; it was not a group of healthy volunteers. In experiments on removed valve tissue and lab-grown cells, calcifying cells released more tiny packets derived from mitochondria. When packets from calcifying cells were transferred to other cultured valve cells, those recipient cells accumulated more mineral deposits.

That transfer experiment is the part that goes beyond simply finding the same protein in damaged tissue. It suggests that a calcifying cell can change its neighbor through material it releases. The experiment took place in culture, though, not in a beating human heart.

One protein, Gas6, helped the packets detach from mitochondria in the lab. In a mouse model in which injury was used to trigger valve disease, animals lacking Gas6 had less valve narrowing and calcification. The mouse result adds evidence for a mechanism in that model. It does not establish that Gas6 causes the same pattern in people or that blocking the protein in an adult would reproduce the effect of deleting the gene in a mouse.

That is the gap to watch. A biological explanation of how disease spreads is useful, but a clinical advance would require a safe intervention that slows meaningful valve deterioration in people, not just one that changes a lab marker. No treatment was tested in patients in this study.

Primary source

Open this article on its own → Cardiovascular Living Magazine →

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗